2445: Poolbeg’s Big Biotech Moment? First Patient Dosed Ahead of Key POLB 001 Data
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Unfollow podcast failed
2445: Poolbeg’s Big Biotech Moment? First Patient Dosed Ahead of Key POLB 001 Data
-
Narrated by:
-
By:
Watch on YouTube
Poolbeg Pharma has dosed the first patient in its POLB 001 TOPICAL clinical trial, marking the start of a key execution phase for its CRS prevention programme. With UCLH activated, further sites expected, interim data targeted for summer 2026 and partnering discussions ongoing, investors will be watching whether clinical progress can validate the programme’s claimed commercial potential.
adbl_web_anon_alc_button_suppression_t1
No reviews yet